Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.
Whilding LM, Parente-Pereira AC, Zabinski T, Davies DM, Petrovic RMG, Kao YV, Saxena SA, Romain A, Costa-Guerra JA, Violette S, Itamochi H, Ghaem-Maghami S, Vallath S, Marshall JF, Maher J. Whilding LM, et al. Among authors: petrovic rmg. Mol Ther. 2017 Jan 4;25(1):259-273. doi: 10.1016/j.ymthe.2016.10.012. Epub 2017 Jan 4. Mol Ther. 2017. PMID: 28129120 Free PMC article.
Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.
Whilding LM, Parente-Pereira AC, Zabinski T, Davies DM, Petrovic RMG, Kao YV, Saxena SA, Romain A, Costa-Guerra JA, Violette S, Itamochi H, Ghaem-Maghami S, Vallath S, Marshall JF, Maher J. Whilding LM, et al. Among authors: petrovic rmg. Mol Ther. 2017 Oct 4;25(10):2427. doi: 10.1016/j.ymthe.2017.09.018. Epub 2017 Sep 23. Mol Ther. 2017. PMID: 28958577 Free PMC article. No abstract available.
Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity?
van der Stegen SJ, Davies DM, Wilkie S, Foster J, Sosabowski JK, Burnet J, Whilding LM, Petrovic RM, Ghaem-Maghami S, Mather S, Jeannon JP, Parente-Pereira AC, Maher J. van der Stegen SJ, et al. J Immunol. 2013 Nov 1;191(9):4589-98. doi: 10.4049/jimmunol.1301523. Epub 2013 Sep 23. J Immunol. 2013. PMID: 24062490
CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.
Thayaparan T, Petrovic RM, Achkova DY, Zabinski T, Davies DM, Klampatsa A, Parente-Pereira AC, Whilding LM, van der Stegen SJ, Woodman N, Sheaff M, Cochran JR, Spicer JF, Maher J. Thayaparan T, et al. Oncoimmunology. 2017 Aug 14;6(12):e1363137. doi: 10.1080/2162402X.2017.1363137. eCollection 2017. Oncoimmunology. 2017. PMID: 29209570 Free PMC article.
Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells.
van der Stegen SJC, Lindenbergh PL, Petrovic RM, Xie H, Diop MP, Alexeeva V, Shi Y, Mansilla-Soto J, Hamieh M, Eyquem J, Cabriolu A, Wang X, Abujarour R, Lee T, Clarke R, Valamehr B, Themeli M, Riviere I, Sadelain M. van der Stegen SJC, et al. Nat Biomed Eng. 2022 Nov;6(11):1284-1297. doi: 10.1038/s41551-022-00915-0. Epub 2022 Aug 8. Nat Biomed Eng. 2022. PMID: 35941192 Free PMC article.